MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2025.03.013

Медицинская библиотека · American heart journal · 2025

Hyperoxemic oxygen therapy in patients with acute anterior myocardial infarction: HOT-AAMI-design and rationale of a randomized trial.

Zeymer Uwe, Hassinger Fathema, Bramlage Peter, Schafer Andreas, Westermann Dirk, Thiele Holger, HOT-AAMI Investigators

Протокол клинического исследованияСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Patients with acute anterior ST-elevation myocardial infarction (STEMI) are at high risk for death and heart failure (HF) despite treatment with primary percutaneous coronary intervention (PCI). Adjunctive therapy with hyperoxemic supersaturated oxygen (SSO2) following PCI reduced infarct size in previous randomized trials, but none of these trials were powered for clinical endpoints.

AIMS: The HOT-AAMI trial evaluates whether hyperoxemic supersaturated oxygen (SSO2) therapy following PCI reduces the risk of death and heart failure.

METHODS

HOT-AAMI is a multicenter, 1:1 randomized, open-label study across 50 sites in Germany. Patients presenting with anterior STEMI and undergoing successful PCI of the left anterior descending artery are randomized to receive SSO2 therapy on top of standard care or standard of care alone. The primary endpoint is a composite of all-cause mortality or unplanned heart failure hospital admission or outpatient visit due to heart failure requiring intravenous diuretic therapy during 12-48 months follow-up. Secondary endpoints include cardiovascular mortality, recurrent myocardial infarction, stroke, and quality of life. The sample size calculation for the HOT-AAMI trial is based on detecting a relative reduction of 25% in the primary composite endpoint. In the control group, a yearly event rate of 16% is expected, comprised of mortality (7%), hospitalization for heart failure (5%), and acute heart failure requiring outpatient treatment (4%). The study is designed to detect this 25% relative difference with a 2-sided significance level of 0.05 and 80% power, requiring a total of 393 events; therefore 1,266 patients will be enrolled.

CONCLUSIONS

The HOT-AAMI trial is the first trial powered to determine whether SSO2 therapy, administered immediately post-PCI, improves death and heart failure outcomes in patients with anterior STEMI.

TRIAL REGISTRATION: HOT-AAMI Clinicaltrials.gov NCT06742684.

Для цитирования: Zeymer Uwe, Hassinger Fathema, Bramlage Peter, Schafer Andreas, Westermann Dirk, Thiele Holger, HOT-AAMI Investigators. Hyperoxemic oxygen therapy in patients with acute anterior myocardial infarction: HOT-AAMI-design and rationale of a randomized trial.. American heart journal. 2025. DOI: 10.1016/j.ahj.2025.03.013.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.